SELLAS Life Sciences Group (NASDAQ: SLS) closed Friday at $15.46, a 15.37% surge that pushed its market capitalization to $3.12 billion. The rally, fueled by anticipation of a pivotal Phase 3 trial readout, brought the stock within 2.6% of its 12-month high.
The company's disclosed cash position of $138.3 million as of June 30 represents just 4.4% of its total valuation. This leaves approximately $2.98 billion in equity value tied to pipeline prospects, primarily the acute myeloid leukemia (AML) programs.
REGAL Trial: The Key Catalyst
The main driver is the REGAL study, a Phase 3 trial evaluating galinpepimut-S as maintenance therapy for AML patients in second remission. The event-driven final analysis will commence once the 80th death is recorded. As of May 11, the trial had reported 78 events, with the company still blinded to treatment assignments.
CEO Angelos Stergiou said the company is "approaching the pre-specified 80th event," after which the database will be locked for a blinded review before unblinding. The exact timing of results remains undisclosed, but investors are closely watching for the event announcement.
Financial Position and Dilution
SELLAS's balance sheet provides near-term financing relief, but the recent cash infusion came at a cost. Outstanding shares rose 31.9% to 201.9 million from 153.1 million at year-end, diluting existing shareholders.
The company's second-quarter net loss widened to $9.6 million from $6.6 million a year earlier, with research expenses jumping 62% to $6.3 million. These figures highlight the financial burn associated with advancing clinical programs.
Analyst Optimism and Price Targets
Recent analyst actions reflect growing confidence. Alliance Global's James Molloy set a $35 price target, implying 126% upside from Friday's close. Maxim Group's Jason McCarthy reiterated a Buy with a $30 target. The consensus among two analysts is $32.50, representing 110% upside.
Alliance Global highlighted SLS009's potential as a CDK9 inhibitor, suggesting a competitive edge in the AML landscape. This optimism contributed to the stock's continued climb despite a valuation analysis flagging the shares as overextended.
Alternative Pipeline: SLS009
Beyond REGAL, SELLAS is developing SLS009, a CDK9 inhibitor for AML. The Phase 2 trial had enrolled 28 of 80 first-line patients as of August 10, with topline data expected in the fourth quarter of 2026. This program offers a secondary catalyst that could diversify pipeline risk.
Market Context and Risks
Friday's trading volume reached 15.06 million shares, 74% above the three-month average, and the stock outperformed the Nasdaq by 14.94 percentage points. The broader market also rose, with the Nasdaq Composite gaining 0.43% to 26,180.46 and the S&P 500 up 0.43% to 7,674.37.
Despite the bullish momentum, risks remain. REGAL could fail to meet its survival endpoint, and SLS009 is not yet approved. Further dilution or increased R&D spending are also possibilities. Investors should monitor the 80th event announcement, which could trigger the final analysis process.
